FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074492690> ?p ?o ?g. }

• W2074492690 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CAClinical trials have shown promising responses of BRCA-linked breast and ovarian cancers to PARP inhibitor therapy, but remissions are often short-lived and incomplete. The PI3K pathway is frequently activated in these malignancies. Recently, we reported in vivo synergy of a PI3K- and a PARP-inhibitor in a mouse model of BRCA1-related breast cancer. While the PARP-inhibitor olaparib alone attenuated tumor growth modestly, a dramatic reduction in tumor growth was observed when olaparib was combined with the PI3K-inhibitor BKM120. In BRCA1-mutant HCC1937 BC cells, PI3K- (but not akt-) inhibition increased indicators of DNA damage, such as poly-ADP-ribosylation and γH2AX, suggesting a critical role of PI3K activity for the maintenance of genomic stability. Here, we report on the molecular mechanism underlying this synergy, on treatment outcomes in an improved mouse model system and the development of an early-phase clinical study. Pre-clinical modeling was done in BRCA1-mutant HCC1937 cells and in a mouse model based on the syngenic transplantation of tumors derived on the K14-Cre BRCA1f/fp53f/f background. Metabolic profiling in vitro and in vivo showed that PI3K-inhibition decreased flux through glycolysis and specifically through the non-oxidative pentose-phosphate pathway, the main source of ribose-5-phosphate required for the de novo synthesis of nucleotides in HCC1937 cells. Within 3 hours and preceding cell cycle changes, BKM120 caused a decrease in nucleotide pools that was further exacerbated by the addition of olaparib. Nucleotide shortage led to to replication stress with the appearance of γH2AX and increased poly-ADP-ribosylation. Tumors with complete loss of BRCA1 and p53 proved particularly vulnerable to this treatment strategy. We were able to induce complete and durable remissions of murine tumors arising on the K14-Cre BRCA1f/fp53f/f background with a 28-day course of BKM120 and Olaparib. These preclinical data have served as the rationale for a phase I, multi-center study ([NCT01623349][1]) combining the oral PARP inhibitor olaparib with the oral PI3-kinase inhibitor BKM120 in patients with recurrent HGSC or recurrent TNBC. The study is being conducted through the Stand Up to Cancer (SU2C)'s Targeting PI3-kinase in Women's Cancers Dream Team. It has a 3 + 3 design, escalating if 0/3 or 1/6 participants have a DLT during the first cycle of therapy. The study objectives are to determine the recommended phase II dose (RP2D) of daily continuous oral olaparib (using the tablet formulation) and BKM120, assess toxicities, safety, and preliminary activity of this combination, and determine pharmacokinetic profiles of both agents as well as translational endpoints. The study serves as an example for the development of a clinical trials concept for TNBC and HGSC based on a close collaboration of basic and clinical scientists through the SU2C mechanism.Citation Format: Gerburg M. Wulf, Ashish Juvekar, Costas A. Lyssiotis, Hai Hu, Sina Yadegarynia, Hui Liu, Baek Kim, Eric Winter, Ralph Scully, John Asara, Lewis C. Cantley, Ursula Matulonis. Combination of a PI3K- and a PARP-inhibitor to treat high-grade serous ovarian or triple-negative breast cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr CT338. doi:10.1158/1538-7445.AM2014-CT338 [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01623349&atom=%2Fcanres%2F74%2F19_Supplement%2FCT338.atom" @default.
• W2074492690 created "2016-06-24" @default.
• W2074492690 creator A5008672750 @default.
• W2074492690 creator A5016571607 @default.
• W2074492690 creator A5018472888 @default.
• W2074492690 creator A5039036817 @default.
• W2074492690 creator A5041241925 @default.
• W2074492690 creator A5044301848 @default.
• W2074492690 creator A5055874211 @default.
• W2074492690 creator A5057032257 @default.
• W2074492690 creator A5058249824 @default.
• W2074492690 creator A5059044712 @default.
• W2074492690 creator A5080610604 @default.
• W2074492690 creator A5090550645 @default.
• W2074492690 date "2014-09-30" @default.
• W2074492690 modified "2023-09-26" @default.
• W2074492690 title "Abstract CT338: Combination of a PI3K- and a PARP-inhibitor to treat high-grade serous ovarian or triple-negative breast cancer" @default.
• W2074492690 doi "https://doi.org/10.1158/1538-7445.am2014-ct338" @default.
• W2074492690 hasPublicationYear "2014" @default.
• W2074492690 type Work @default.
• W2074492690 sameAs 2074492690 @default.
• W2074492690 citedByCount "1" @default.
• W2074492690 countsByYear W20744926902016 @default.
• W2074492690 crossrefType "proceedings-article" @default.
• W2074492690 hasAuthorship W2074492690A5008672750 @default.
• W2074492690 hasAuthorship W2074492690A5016571607 @default.
• W2074492690 hasAuthorship W2074492690A5018472888 @default.
• W2074492690 hasAuthorship W2074492690A5039036817 @default.
• W2074492690 hasAuthorship W2074492690A5041241925 @default.
• W2074492690 hasAuthorship W2074492690A5044301848 @default.
• W2074492690 hasAuthorship W2074492690A5055874211 @default.
• W2074492690 hasAuthorship W2074492690A5057032257 @default.
• W2074492690 hasAuthorship W2074492690A5058249824 @default.
• W2074492690 hasAuthorship W2074492690A5059044712 @default.
• W2074492690 hasAuthorship W2074492690A5080610604 @default.
• W2074492690 hasAuthorship W2074492690A5090550645 @default.
• W2074492690 hasConcept C104317684 @default.
• W2074492690 hasConcept C121608353 @default.
• W2074492690 hasConcept C126322002 @default.
• W2074492690 hasConcept C134935766 @default.
• W2074492690 hasConcept C182979987 @default.
• W2074492690 hasConcept C2778502085 @default.
• W2074492690 hasConcept C2779138821 @default.
• W2074492690 hasConcept C2779962180 @default.
• W2074492690 hasConcept C2780427987 @default.
• W2074492690 hasConcept C502942594 @default.
• W2074492690 hasConcept C530470458 @default.
• W2074492690 hasConcept C55493867 @default.
• W2074492690 hasConcept C62478195 @default.
• W2074492690 hasConcept C71924100 @default.
• W2074492690 hasConcept C75217442 @default.
• W2074492690 hasConcept C82381507 @default.
• W2074492690 hasConcept C86554907 @default.
• W2074492690 hasConcept C86803240 @default.
• W2074492690 hasConcept C95444343 @default.
• W2074492690 hasConceptScore W2074492690C104317684 @default.
• W2074492690 hasConceptScore W2074492690C121608353 @default.
• W2074492690 hasConceptScore W2074492690C126322002 @default.
• W2074492690 hasConceptScore W2074492690C134935766 @default.
• W2074492690 hasConceptScore W2074492690C182979987 @default.
• W2074492690 hasConceptScore W2074492690C2778502085 @default.
• W2074492690 hasConceptScore W2074492690C2779138821 @default.
• W2074492690 hasConceptScore W2074492690C2779962180 @default.
• W2074492690 hasConceptScore W2074492690C2780427987 @default.
• W2074492690 hasConceptScore W2074492690C502942594 @default.
• W2074492690 hasConceptScore W2074492690C530470458 @default.
• W2074492690 hasConceptScore W2074492690C55493867 @default.
• W2074492690 hasConceptScore W2074492690C62478195 @default.
• W2074492690 hasConceptScore W2074492690C71924100 @default.
• W2074492690 hasConceptScore W2074492690C75217442 @default.
• W2074492690 hasConceptScore W2074492690C82381507 @default.
• W2074492690 hasConceptScore W2074492690C86554907 @default.
• W2074492690 hasConceptScore W2074492690C86803240 @default.
• W2074492690 hasConceptScore W2074492690C95444343 @default.
• W2074492690 hasLocation W20744926901 @default.
• W2074492690 hasOpenAccess W2074492690 @default.
• W2074492690 hasPrimaryLocation W20744926901 @default.
• W2074492690 hasRelatedWork W1493855943 @default.
• W2074492690 hasRelatedWork W1500635242 @default.
• W2074492690 hasRelatedWork W1830954189 @default.
• W2074492690 hasRelatedWork W2016425953 @default.
• W2074492690 hasRelatedWork W2121209739 @default.
• W2074492690 hasRelatedWork W2258601828 @default.
• W2074492690 hasRelatedWork W2334222868 @default.
• W2074492690 hasRelatedWork W2489500024 @default.
• W2074492690 hasRelatedWork W2566264318 @default.
• W2074492690 hasRelatedWork W2601536553 @default.
• W2074492690 hasRelatedWork W2604158559 @default.
• W2074492690 hasRelatedWork W2622647107 @default.
• W2074492690 hasRelatedWork W2740259225 @default.
• W2074492690 hasRelatedWork W2740475656 @default.
• W2074492690 hasRelatedWork W2740829094 @default.
• W2074492690 hasRelatedWork W2885154135 @default.
• W2074492690 hasRelatedWork W2887083728 @default.
• W2074492690 hasRelatedWork W2955624827 @default.
• W2074492690 hasRelatedWork W3083020631 @default.
• W2074492690 hasRelatedWork W3092148632 @default.
• W2074492690 isParatext "false" @default.
• W2074492690 isRetracted "false" @default.
• W2074492690 magId "2074492690" @default.

• next